For children with aggressive Burkitt lymphoma and other B-cell non-Hodgkin lymphomas, adding rituximab (Rituxan, Truxima) to chemotherapy substantially increases the likelihood of the child being cured, results from a large clinical trial show.
from Cancer Currents: An NCI Cancer Research Blog https://ift.tt/2NLem6K
from Cancer Currents: An NCI Cancer Research Blog https://ift.tt/2NLem6K